ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in Muscle-Invasive bladder cancer

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Koga, Fumitaka ^a   Yoshida, Soichiro ^a   Tatokoro, Manabu ^a   Kawakami, Satoru ^a   Fujii, Yasuhisa ^a   Kumagai, Jiro ^a   Neckers, Len ^b   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER RESISTANCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DEATH; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYDRONEPHROSIS; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; RISK FACTOR; BLADDER TUMOR; CANCER INVASION; COMPARATIVE STUDY; DRUG RESISTANCE; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; MUSCLE TUMOR; PROGNOSIS; RADIATION DOSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NF-KAPPA B; PROGNOSIS; RADIATION TOLERANCE; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 80755176829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027616     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Lee R, Droller MJ, (2000) The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 27: 1-13, vii.
3. Krause FS, Walter B, Ott OJ, Haberle L, Weiss C, et al. (2011) 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res 31: 985-990.
4. Rodel C, Weiss C, Sauer R, (2006) Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24: 5536-5544.
5. Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM, (2003) Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 97: 2115-2119.
6. Sandler HM, Mirhadi AJ, (2010) Current status of radiation therapy for bladder cancer. Expert Rev Anticancer Ther 10: 895-901.
7. Koga F, Yoshida S, Kawakami S, Kageyama Y, Yokoyama M, et al. (2008) Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis. Urology 72: 384-388.
8. Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, et al. (2005) Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62: 309-317.
9. Kawashima A, Nakayama M, Kakuta Y, Abe T, Hatano K, et al. (2011) Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res 17: 2561-2569.
10. Matsumoto H, Matsuyama H, Fukunaga K, Yoshihiro S, Wada T, et al. (2004) Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer. Br J Cancer 91: 1025-1031.
11. Matsumoto H, Wada T, Fukunaga K, Yoshihiro S, Matsuyama H, et al. (2004) Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol 34: 124-130.
12. Rodel C, Grabenbauer GG, Rodel F, Birkenhake S, Kuhn R, et al. (2000) Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 46: 1213-1221.
13. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, et al. (2006) Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 5: 2844-2850.
14. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, et al. (2006) Association of activated transcription factor nuclear factor kappa B with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24: 748-754.
15. Lara PC, Perez S, Rey A, Santana C, (1999) Apoptosis in carcinoma of the bladder: relation with radiation treatment results. Int J Radiat Oncol Biol Phys 43: 1015-1019.
16. Lara PC, Rey A, Santana C, Afonso JL, Diaz JM, et al. (1998) The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Radiother Oncol 49: 163-167.
17. Moonen L, Ong F, Gallee M, Verheij M, Horenblas S, et al. (2001) Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 49: 1305-1310.
18. Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, et al. (2001) Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol 61: 169-175.
19. Weiss C, von Romer F, Capalbo G, Ott OJ, Wittlinger M, et al. (2009) Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 74: 1455-1460.
20. Wijkstrom H, Tribukait B, (1990) Deoxyribonucleic acid flow cytometry in predicting response to radical radiotherapy of bladder cancer. J Urol 144: 646-650; discussion 650-651.
21. Koga F, Kihara K, Fujii Y, Yoshida S, Saito K, et al. (2009) Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study. BJU Int 104: 189-194.
22. Koga F, Kihara K, Yoshida S, Yokoyama M, Saito K, et al. (2011) Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int. [Epub ahead of print].
23. Sobin LH, Wittekind C, eds. (2002) Classification of Malignant Tumours. 6th ed. New York Wiley-Liss.
24. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, et al. (2003) Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 9: 5501-5507.
25. Esrig D, Spruck CH 3rd, Nichols PW, Chaiwun B, Steven K, et al. (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143: 1389-1397.
26. Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, et al. (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20: 3061-3071.
27. Marmor MD, Skaria KB, Yarden Y, (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903-913.
28. Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, et al. (2002) HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 102: 514-518.
29. Lin Y, Bai L, Chen W, Xu S, (2010) The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 14: 45-55.
30. Levidou G, Saetta AA, Korkolopoulou P, Papanastasiou P, Gioti K, et al. (2008) Clinical significance of nuclear factor (NF)-kappaB levels in urothelial carcinoma of the urinary bladder. Virchows Arch 452: 295-304.
31. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
32. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
33. Koga F, Kihara K, Neckers L, (2009) Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 29: 797-807.
34. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM, (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91: 8324-8328.
35. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, et al. (2011) Potential Role of Heat Shock Protein 90 Inhibitors to Overcome Chemoradiotherapy Resistance Associated with Her-2 and Nf-Kappa B Overexpression in Muscle-Invasive Bladder Cancer. Eur Urol Suppl 10: 167-167.
36. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, et al. (2011) A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. [Epub ahead of print].